pantoprazole has been researched along with Curling Ulcer in 77 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This trial was performed to compare the effects of IV pantoprazole versus omeprazole on 24-hour intragastric acidity in Chinese patients with endoscopically confirmed duodenal ulcer." | 9.12 | Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial. ( Cheng, YC; Lin, HJ; Lo, WC; Perng, CL, 2006) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 9.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| "A total of 222 patients with active duodenal ulcers (DU) were randomly allocated to a double dummy blind treatment, either with ranitidine (RAN) 300 mg (111, aged from 20-68 yr old, 56 female) or with pantoprazole (PANT) 40 mg (111 patients, 18-70 yr old, 45 female)." | 9.09 | Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. ( de Paula Castro, L; Lyra, LG; Malafaia, O; Meneghelli, UG; Zaterka, S, 2000) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 9.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| "Pantoprazole is clinically superior to ranitidine in the treatment of acute duodenal ulcer, in terms of both healing and symptom relief." | 9.08 | Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. ( Classen, M; Schepp, W, 1995) |
| "A double-blind, randomized, multicenter, multicountry study (Poland, Chech Republic, Hungary) was carried out in 1995 on patients (n = 326) with endoscopically confirmed duodenal ulcer treated with ranitidine vs." | 9.08 | [Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study]. ( Döbrönte, Z; Juhász, L; Lonovics, J; Papp, J, 1997) |
| "In an open two-centre study, 60 duodenal ulcer patients were treated with pantoprazole 40 mg b." | 9.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "The healing rate of duodenal ulcer with pantoprazole monotherapy (40 mg before breakfast) was significantly higher than with ranitidine (300 mg before bedtime)." | 9.08 | [Treatment of duodenal ulcer with pantoprazole. A multicenter study]. ( Dítĕ, P; Drazná, E; Dufek, V; Dvorák, M; Fric, P; Huslarová, A; Jirásek, V; Kunovská, M; Münzová, H; Pelech, T; Petrtýl, J; Roth, Z; Svoboda, J; Zádorová, Z; Zavoral, M, 1996) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 9.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| " Pantoprazole, 40 mg, was compared with the H2-receptor antagonist ranitidine, 300 mg, in the healing of acute duodenal ulcer." | 9.08 | A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. ( Cremer, M; Delle Fave, G; Lambert, R; Lamers, CB; Maier, C, 1995) |
| "Pantoprazole was shown to be a highly-effective and well-tolerated treatment for acute duodenal ulcer." | 9.08 | Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. ( Rehner, M; Rohner, HG; Schepp, W, 1995) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Pantoprazole 40 mg at breakfast is superior to ranitidine 300 mg at bedtime in the short-term treatment of acute, uncomplicated duodenal ulcer." | 9.07 | Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. ( Judmaier, G; Koelz, HR, 1994) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 8.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 7.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| "3%) and there were no serious adverse events." | 6.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| " There was also a clear dose-dependent pharmacodynamic effect, which augmented on moving from the lowest dosage of 20 mg o." | 6.69 | Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. ( Bisso, G; Celle, G; Fiorucci, S; Malesci, A; Mela, GS; Pivari, M; Savarino, V; Termini, R; Usai, P; Vigneri, S; Zentilin, P, 1998) |
| "Pantoprazole is a newly developed benzimidazole derivative with strong inhibitory actions on gastric acid secretion by blocking H(+)-K(+)-ATPase." | 6.67 | Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. ( Khalil, H; Leucht, U; Lühmann, R; Müller, P; Schneider, A; Simon, B, 1992) |
| "Duodenal ulcers were induced in Sprague-Dawley rats by intragastric administration of 500 mg/kg cysteamine-HCl." | 5.39 | Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model. ( Hahm, KB; Han, YM; Kangwan, N; Kim, EH; Kim, JS; Kim, TS; Kim, YJ; Kwon, O; Park, JM, 2013) |
| "This trial was performed to compare the effects of IV pantoprazole versus omeprazole on 24-hour intragastric acidity in Chinese patients with endoscopically confirmed duodenal ulcer." | 5.12 | Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial. ( Cheng, YC; Lin, HJ; Lo, WC; Perng, CL, 2006) |
| "To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 5.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| "In this open, randomized, monocenter, parallel group comparison, 107 patients with duodenal ulcer or functional dyspepsia were assigned to receive one of the following treatment regimens: a 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid, which was either preceded or followed by a 7-day therapy with pantoprazole, 40 mg (P-PCM or PCM-P)." | 5.09 | Pantoprazole suppresses Helicobacter pylori without affecting cure. ( Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999) |
| "A total of 222 patients with active duodenal ulcers (DU) were randomly allocated to a double dummy blind treatment, either with ranitidine (RAN) 300 mg (111, aged from 20-68 yr old, 56 female) or with pantoprazole (PANT) 40 mg (111 patients, 18-70 yr old, 45 female)." | 5.09 | Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. ( de Paula Castro, L; Lyra, LG; Malafaia, O; Meneghelli, UG; Zaterka, S, 2000) |
| "For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b." | 5.09 | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 5.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| "5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks." | 5.09 | Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000) |
| " Pantoprazole, 40 mg, was compared with the H2-receptor antagonist ranitidine, 300 mg, in the healing of acute duodenal ulcer." | 5.08 | A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. ( Cremer, M; Delle Fave, G; Lambert, R; Lamers, CB; Maier, C, 1995) |
| "The healing rate of duodenal ulcer with pantoprazole monotherapy (40 mg before breakfast) was significantly higher than with ranitidine (300 mg before bedtime)." | 5.08 | [Treatment of duodenal ulcer with pantoprazole. A multicenter study]. ( Dítĕ, P; Drazná, E; Dufek, V; Dvorák, M; Fric, P; Huslarová, A; Jirásek, V; Kunovská, M; Münzová, H; Pelech, T; Petrtýl, J; Roth, Z; Svoboda, J; Zádorová, Z; Zavoral, M, 1996) |
| "Pantoprazole was shown to be a highly-effective and well-tolerated treatment for acute duodenal ulcer." | 5.08 | Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. ( Rehner, M; Rohner, HG; Schepp, W, 1995) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 5.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| "In an open two-centre study, 60 duodenal ulcer patients were treated with pantoprazole 40 mg b." | 5.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "A double-blind, randomized, multicenter, multicountry study (Poland, Chech Republic, Hungary) was carried out in 1995 on patients (n = 326) with endoscopically confirmed duodenal ulcer treated with ranitidine vs." | 5.08 | [Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study]. ( Döbrönte, Z; Juhász, L; Lonovics, J; Papp, J, 1997) |
| "Pantoprazole is clinically superior to ranitidine in the treatment of acute duodenal ulcer, in terms of both healing and symptom relief." | 5.08 | Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. ( Classen, M; Schepp, W, 1995) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Pantoprazole 40 mg at breakfast is superior to ranitidine 300 mg at bedtime in the short-term treatment of acute, uncomplicated duodenal ulcer." | 5.07 | Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. ( Judmaier, G; Koelz, HR, 1994) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 4.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| "The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease." | 4.79 | Clinical efficacy of pantoprazole compared with ranitidine. ( Bader, JP; Delchier, JC, 1994) |
| "We present the case of a patient taking aspirin and etoricoxib who was admitted with upper digestive haemorrhage due to duodenal ulcer." | 3.75 | Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors. ( Soares, J, 2009) |
| "The results of treatment of duodenal ulcers and gastroesophageal reflux disease with using of modern proton pump inhibitor controloc (pantoprazole) are presented in this article." | 3.72 | [Efficacy of controloc in the treatment of acid-dependent diseases]. ( Agibalov, AN; Chubenko, SS; Gaĭdukov, VO; Onishenko, AV, 2003) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 3.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| "The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated." | 3.68 | Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. ( Dorrian, CA; Fullarton, GM; Harwood, J; Macdonald, AM; McColl, KE; Nujumi, AM, 1992) |
| "pantoprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "3%) and there were no serious adverse events." | 2.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| " There was also a clear dose-dependent pharmacodynamic effect, which augmented on moving from the lowest dosage of 20 mg o." | 2.69 | Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. ( Bisso, G; Celle, G; Fiorucci, S; Malesci, A; Mela, GS; Pivari, M; Savarino, V; Termini, R; Usai, P; Vigneri, S; Zentilin, P, 1998) |
| "Pantoprazole is a newly developed benzimidazole derivative with strong inhibitory actions on gastric acid secretion by blocking H(+)-K(+)-ATPase." | 2.67 | Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. ( Khalil, H; Leucht, U; Lühmann, R; Müller, P; Schneider, A; Simon, B, 1992) |
| " Available data indicate that PPIs appear to have similar potency on a milligram basis, and that omeprazole and lansoprazole are more frequently double dosed than pantoprazole." | 2.41 | The clinical importance of proton pump inhibitor pharmacokinetics. ( Thomson, AB; Yacyshyn, BR, 2002) |
| " Pantoprazole is well absorbed when administered as an enteric-coated, delayed-release tablet, with an oral bioavailability of approximately 77%." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| "Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion." | 2.39 | Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. ( Fitton, A; Wiseman, L, 1996) |
| " Pantoprazole formulated in an enteric-coated tablet displays high bioavailability and linear pharmacokinetics whether on single or multiple dose regimens." | 2.39 | Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. ( Huber, R; Kohl, B; Sachs, G; Senn-Bilfinger, J; Simon, WA; Sturm, E, 1995) |
| "Duodenal ulcers were induced in Sprague-Dawley rats by intragastric administration of 500 mg/kg cysteamine-HCl." | 1.39 | Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model. ( Hahm, KB; Han, YM; Kangwan, N; Kim, EH; Kim, JS; Kim, TS; Kim, YJ; Kwon, O; Park, JM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (41.56) | 18.2507 |
| 2000's | 38 (49.35) | 29.6817 |
| 2010's | 7 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JM | 2 |
| Kim, YJ | 1 |
| Kim, JS | 1 |
| Han, YM | 1 |
| Kangwan, N | 1 |
| Hahm, KB | 1 |
| Kim, TS | 1 |
| Kwon, O | 1 |
| Kim, EH | 1 |
| Taş, A | 1 |
| Lanas, A | 1 |
| Carrera-Lasfuentes, P | 1 |
| García-Rodríguez, LA | 1 |
| García, S | 1 |
| Arroyo-Villarino, MT | 1 |
| Ponce, J | 1 |
| Bujanda, L | 1 |
| Calleja, JL | 1 |
| Polo-Tomas, M | 1 |
| Calvet, X | 1 |
| Feu, F | 1 |
| Perez-Aisa, A | 1 |
| Chan, CC | 1 |
| Chien, NH | 1 |
| Lee, CL | 1 |
| Yang, YC | 1 |
| Hung, CS | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Chao, HC | 1 |
| Yu, WL | 1 |
| Yüksel, I | 1 |
| Ataseven, H | 1 |
| Köklü, S | 1 |
| Ertuğrul, I | 1 |
| Başar, O | 1 |
| Odemiş, B | 1 |
| Ibiş, M | 1 |
| Saşmaz, N | 1 |
| Sahin, B | 1 |
| Khafizov, NKh | 1 |
| Kal'met'eva, LP | 1 |
| Ziganshina, ZIa | 1 |
| Baĭnak, OV | 1 |
| Pellicano, R | 1 |
| Sharova, EP | 1 |
| Tan, VP | 1 |
| Wong, BC | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| U-Saif, R | 1 |
| Khan, BA | 1 |
| Yatoo, GN | 1 |
| Shah, AH | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Silva, AP | 1 |
| Soares, J | 1 |
| Kim, JY | 1 |
| Kim, N | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Lee, DH | 1 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Lee, JH | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Fakheri, H | 1 |
| Taghvaei, T | 1 |
| Hosseini, V | 1 |
| Bari, Z | 1 |
| Wu, XP | 1 |
| He, JR | 1 |
| Wang, CL | 1 |
| Ling, QH | 1 |
| Yacyshyn, BR | 1 |
| Thomson, AB | 2 |
| Hiramoto, JS | 1 |
| Terdiman, JP | 1 |
| Norton, JA | 1 |
| Boixeda, D | 1 |
| Martín De Argila, C | 1 |
| Bermejo, F | 1 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 1 |
| García Plaza, A | 1 |
| Chubenko, SS | 1 |
| Gaĭdukov, VO | 1 |
| Agibalov, AN | 1 |
| Onishenko, AV | 1 |
| Yukselen, V | 1 |
| Yasa, MH | 1 |
| Karaoglu, AO | 1 |
| Ghazzawi, IM | 1 |
| Obeidat, WA | 1 |
| Zuriekat, FA | 1 |
| Sivri, B | 1 |
| Simsek, I | 1 |
| Hulagu, S | 1 |
| Kadayifci, A | 1 |
| Tozun, N | 1 |
| Akarsu, M | 1 |
| Uraz, S | 1 |
| Savas, MC | 1 |
| Koruk, M | 1 |
| Bozbas, A | 1 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Aladağ, M | 1 |
| Kantarçeken, B | 1 |
| Karincaoğlu, M | 1 |
| Sertkaya, A | 1 |
| Cikim, K | 1 |
| Harputluoğlu, MM | 1 |
| Demirel, U | 1 |
| Alan, H | 1 |
| Ateş, F | 1 |
| Yildirim, B | 1 |
| Hilmioğlu, F | 1 |
| Jensen, DM | 1 |
| Pace, SC | 1 |
| Soffer, E | 1 |
| Comer, GM | 1 |
| Lin, HJ | 1 |
| Lo, WC | 1 |
| Cheng, YC | 1 |
| Perng, CL | 1 |
| Yilmaz, S | 1 |
| Bayan, K | 1 |
| Dursun, M | 1 |
| Canoruç, F | 1 |
| Kilinç, N | 1 |
| Tüzün, Y | 1 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Oh, JH | 1 |
| Choi, MG | 1 |
| Dong, MS | 1 |
| Paik, CN | 1 |
| Cho, YK | 1 |
| Jeong, JJ | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Han, SW | 1 |
| Choi, KY | 1 |
| Chung, IS | 1 |
| Dam, C | 1 |
| Bygum, A | 1 |
| Schepp, W | 3 |
| Classen, M | 1 |
| Beker, JA | 1 |
| Bianchi Porro, G | 2 |
| Bigard, MA | 1 |
| Delle Fave, G | 2 |
| Devis, G | 1 |
| Gouerou, H | 1 |
| Maier, C | 2 |
| Cremer, M | 1 |
| Lambert, R | 1 |
| Lamers, CB | 1 |
| Adamek, RJ | 3 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| Opferkuch, W | 1 |
| Ricken, D | 1 |
| Wegener, M | 1 |
| Bader, JP | 1 |
| Delchier, JC | 1 |
| Rehner, M | 2 |
| Witzel, L | 1 |
| Brunner, G | 1 |
| Harke, U | 1 |
| Judmaier, G | 1 |
| Koelz, HR | 1 |
| Huber, R | 1 |
| Kohl, B | 1 |
| Sachs, G | 1 |
| Senn-Bilfinger, J | 1 |
| Simon, WA | 1 |
| Sturm, E | 1 |
| Rohner, HG | 1 |
| Fitton, A | 1 |
| Wiseman, L | 1 |
| Fric, P | 1 |
| Huslarová, A | 1 |
| Dítĕ, P | 1 |
| Jirásek, V | 1 |
| Roth, Z | 1 |
| Svoboda, J | 1 |
| Drazná, E | 1 |
| Dufek, V | 1 |
| Dvorák, M | 1 |
| Kunovská, M | 1 |
| Münzová, H | 1 |
| Pelech, T | 1 |
| Petrtýl, J | 1 |
| Zádorová, Z | 1 |
| Zavoral, M | 1 |
| Labenz, J | 1 |
| Tillenburg, B | 1 |
| Weismüller, J | 1 |
| Lütke, A | 1 |
| Stolte, M | 2 |
| Papp, J | 1 |
| Döbrönte, Z | 1 |
| Juhász, L | 1 |
| Lonovics, J | 1 |
| Glaser, J | 1 |
| Hein, J | 1 |
| Daikeler, R | 1 |
| Weithofer, G | 1 |
| Vieth, M | 1 |
| Schmidt, M | 1 |
| Treiber, G | 1 |
| Lambert, JR | 1 |
| Louw, JA | 1 |
| van Rensburg, CJ | 1 |
| Hanslo, D | 1 |
| Grundlings, HD | 1 |
| Girdwood, AH | 1 |
| Marks, IN | 1 |
| Ellenrieder, V | 1 |
| Fensterer, H | 1 |
| Waurick, M | 1 |
| Adler, G | 1 |
| Glasbrenner, B | 1 |
| Pazzi, P | 1 |
| Scagliarini, R | 1 |
| Gamberini, S | 1 |
| Matarese, V | 1 |
| Rizzo, C | 1 |
| Gullini, S | 1 |
| Bethke, TD | 1 |
| Savarino, V | 1 |
| Mela, GS | 1 |
| Zentilin, P | 1 |
| Bisso, G | 1 |
| Pivari, M | 1 |
| Vigneri, S | 1 |
| Termini, R | 1 |
| Fiorucci, S | 1 |
| Usai, P | 1 |
| Malesci, A | 1 |
| Celle, G | 1 |
| Takeuchi, K | 1 |
| Konaka, A | 1 |
| Nishijima, M | 1 |
| Kato, S | 1 |
| Yasuhiro, T | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Kromer, W | 2 |
| Horbach, S | 1 |
| Lühmann, R | 3 |
| Catalano, F | 2 |
| Branciforte, G | 2 |
| Catanzaro, R | 2 |
| Bentivegna, C | 2 |
| Cipolla, R | 2 |
| Nuciforo, G | 2 |
| Brogna, A | 2 |
| Rodríguez Téllez, M | 1 |
| Valenzuela Barranco, M | 1 |
| Caballero Plasencia, A | 1 |
| Martín Ruiz, J | 1 |
| López-Andrade, A | 1 |
| Carmona Soria, I | 1 |
| Herrerías Gutiérrez, J | 1 |
| Vcev, A | 2 |
| Stimac, D | 2 |
| Ivandić, A | 2 |
| Vceva, A | 2 |
| Takac, B | 2 |
| Pezerović, D | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Meneghelli, UG | 1 |
| Zaterka, S | 1 |
| de Paula Castro, L | 1 |
| Malafaia, O | 1 |
| Lyra, LG | 1 |
| Dammann, HG | 1 |
| Fölsch, UR | 1 |
| Hahn, EG | 1 |
| von Kleist, DH | 1 |
| Klör, HU | 1 |
| Kirchner, T | 1 |
| Strobel, S | 1 |
| Kist, M | 1 |
| Gisbert, JP | 1 |
| Carpio, D | 1 |
| Marcos, S | 1 |
| Gisbert, JL | 1 |
| García Grávalos, R | 1 |
| Pajares, JM | 1 |
| Vukobrat-Bijedić, Z | 1 |
| Lacević, N | 1 |
| Bratović, I | 1 |
| Gribajcević, M | 1 |
| Gogov, B | 1 |
| Radović, S | 1 |
| Frevel, M | 1 |
| Daake, H | 1 |
| Janisch, HD | 1 |
| Kellner, HU | 1 |
| Krezdorn, HG | 1 |
| Tanneberger, D | 1 |
| Wack, R | 1 |
| Lazzaroni, M | 1 |
| Imbesi, V | 1 |
| Montrone, F | 1 |
| Santagada, T | 1 |
| Jungnickel, PW | 1 |
| Bardou, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Kurbel, S | 1 |
| Ostojić, R | 1 |
| Barbir, A | 1 |
| Hovat, D | 1 |
| Mihaljević, S | 1 |
| Gościmski, A | 1 |
| Matras, J | 1 |
| Wallner, G | 1 |
| Bliesath, H | 1 |
| Simon, B | 2 |
| Hartmann, M | 1 |
| Müller, P | 2 |
| Schneider, A | 2 |
| Wurst, W | 1 |
| Khalil, H | 1 |
| Leucht, U | 1 |
| McColl, KE | 1 |
| Nujumi, AM | 1 |
| Dorrian, CA | 1 |
| Macdonald, AM | 1 |
| Fullarton, GM | 1 |
| Harwood, J | 1 |
| Gönne, S | 1 |
| Riedel, R | 1 |
| Postius, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for pantoprazole and Curling Ulcer
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
The clinical importance of proton pump inhibitor pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost Savings; Duodenal U | 2002 |
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D | 2003 |
Clinical efficacy of pantoprazole compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1994 |
A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Metho | 1994 |
Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Humans; | 1995 |
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1996 |
Pantoprazole--a third proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme I | 1997 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
41 trials available for pantoprazole and Curling Ulcer
| Article | Year |
|---|---|
Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 2008 |
[Use of sunpraz in treating duodenal ulcer: performance test report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Male; Mi | 2008 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarith | 2012 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2006 |
Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2006 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2007 |
Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Ulcer A | 1995 |
Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; | 1995 |
A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Aged; Anti-Ulcer Agents; | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Double-B | 1994 |
Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Duodenal Ulcer; En | 1995 |
[Treatment of duodenal ulcer with pantoprazole. A multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 1996 |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1997 |
[Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Duo | 1997 |
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Doubl | 1998 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1999 |
Pantoprazole suppresses Helicobacter pylori without affecting cure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Thera | 1999 |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2000 |
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2001 |
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans; | 2002 |
Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 1992 |
Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Benzimi | 1992 |
21 other studies available for pantoprazole and Curling Ulcer
| Article | Year |
|---|---|
Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbo | 2013 |
Thrombocytopenia as a side effect of pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Duodenal Ulcer; Humans; Male; | 2013 |
Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Adult; A | 2014 |
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
Cytomegalovirus-infected duodenal ulcer with severe recurrent bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus In | 2016 |
[Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Gastric Aci | 2008 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
Recurrent duodenal ulcer due to nonsteroidal anti-inflammatories following the suspension of antiulcer medication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
[Effect of pantoprazole on non-variceal bleeding].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2000 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
[Efficacy of controloc in the treatment of acid-dependent diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 2003 |
Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Develop | 2004 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans | 2008 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Bi | 1999 |
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Benzimidazoles; Duodenal Ulcer; | 1992 |
Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1990 |